Monday, May 13, 2024
1 p.m. ET

Join Edgewise's Chief Scientific Officer and Chief Medical Officer to learn more about the company’s novel approach designed to protect muscle in individuals living with Becker muscular dystrophy. The webinar will highlight EDG-5506 (Sevasemten) an investigational compound, in the form of a daily oral pill, that could be used alone or in combination with other therapies, regardless of mutation. Hear results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy and learn more about their currently enrolling trial, GRAND CANYON, a phase 2 trial for adults living with Becker.